Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GDC-0810 |
Synonyms | |
Therapy Description |
Brilanestrant (GDC-0810) binds to estrogen receptors and promotes their degradation, potentially resulting in decreased growth of estrogen receptor-expressing tumor cells (PMID: 31266752). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GDC-0810 | ARN-810|Brilanestrant|GDC0810|GDC 0810|ARN 810|ARN810|RO7056118 | Hormone - Anti-estrogens 29 | Brilanestrant (GDC-0810) binds to estrogen receptors and promotes their degradation, potentially resulting in decreased growth of estrogen receptor-expressing tumor cells (PMID: 31266752). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01823835 | Phase II | GDC-0810 | A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | Terminated | USA | NLD | ESP | 1 |
NCT02569801 | Phase II | GDC-0810 Fulvestrant | A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy | Terminated | USA | GBR | ESP | DEU | AUS | 1 |